» Articles » PMID: 36835384

Approaches in Hydroxytyrosol Supplementation on Epithelial-Mesenchymal Transition in TGFβ1-Induced Human Respiratory Epithelial Cells

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Feb 25
PMID 36835384
Authors
Affiliations
Soon will be listed here.
Abstract

Hydroxytyrosol (HT) is an olive polyphenol with anti-inflammatory and antioxidant properties. This study aimed to investigate the effect of HT treatment on epithelial-mesenchymal transition (EMT) in primary human respiratory epithelial cells (RECs) isolated from human nasal turbinate. HT dose-response study and growth kinetic study on RECs was performed. Several approaches on HT treatment and TGFβ1 induction with varying durations and methods was studied. RECs morphology and migration ability were evaluated. Vimentin and E-cadherin immunofluorescence staining and Western blotting [E-cadherin, vimentin, SNAIL/SLUG, AKT, phosphorylated (p)AKT, SMAD2/3 and pSMAD2/3] were performed after 72-h treatment. In silico analysis (molecular docking) of HT was performed to evaluate the potential of HT to bind with the TGFβ receptor. The viability of the HT-treated RECs was concentration-dependent, where the median effective concentration (EC) was 19.04 μg/mL. Testing of the effects of 1 and 10 µg/mL HT revealed that HT suppressed expression of the protein markers vimentin and SNAIL/SLUG while preserving E-cadherin protein expression. Supplementation with HT protected against SMAD and AKT pathway activation in the TGFβ1-induced RECs. Furthermore, HT demonstrated the potential to bind with ALK5 (a TGFβ receptor component) in comparison to oleuropein. TGFβ1-induced EMT in RECs and HT exerted a positive effect in modulating the effects of EMT.

Citing Articles

Hydroxytyrosol: A Promising Therapeutic Agent for Mitigating Inflammation and Apoptosis.

Batarfi W, Mohd Yunus M, A Hamid A, Lee Y, Maarof M Pharmaceutics. 2025; 16(12.

PMID: 39771483 PMC: 11728517. DOI: 10.3390/pharmaceutics16121504.


An Antibody of the Secreted Isoform of Disintegrin and Metalloprotease 9 (sADAM9) Inhibits Epithelial-Mesenchymal Transition and Migration of Prostate Cancer Cell Lines.

Jotatsu Y, Sung S, Wu M, Takeda S, Hirata Y, Maeda K Int J Mol Sci. 2024; 25(12).

PMID: 38928352 PMC: 11203924. DOI: 10.3390/ijms25126646.


Role of Olive Bioactive Compounds in Respiratory Diseases.

Vijakumaran U, Goh N, Razali R, Abdullah N, Yazid M, Sulaiman N Antioxidants (Basel). 2023; 12(6).

PMID: 37371870 PMC: 10295110. DOI: 10.3390/antiox12061140.


Maximizing Postoperative Recovery: The Role of Functional Biomaterials as Nasal Packs-A Comprehensive Systematic Review without Meta-Analysis (SWiM).

Razali R, Vijakumaran U, Fauzi M, Lokanathan Y Pharmaceutics. 2023; 15(5).

PMID: 37242776 PMC: 10223949. DOI: 10.3390/pharmaceutics15051534.

References
1.
Razali R, Lokanathan Y, Yazid M, Ansari A, Saim A, Idrus R . Modulation of Epithelial to Mesenchymal Transition Signaling Pathways by and Its Active Compounds. Int J Mol Sci. 2019; 20(14). PMC: 6679150. DOI: 10.3390/ijms20143492. View

2.
Konnecke M, Burmeister M, Pries R, Boscke R, Bruchhage K, Ungefroren H . Epithelial-Mesenchymal Transition in Chronic Rhinosinusitis: Differences Revealed Between Epithelial Cells from Nasal Polyps and Inferior Turbinates. Arch Immunol Ther Exp (Warsz). 2016; 65(2):157-173. DOI: 10.1007/s00005-016-0409-7. View

3.
Kandagalla S, Sharath B, Bharath B, Hani U, Manjunatha H . Molecular docking analysis of curcumin analogues against kinase domain of ALK5. In Silico Pharmacol. 2018; 5(1):15. PMC: 5755696. DOI: 10.1007/s40203-017-0034-0. View

4.
Lo U, Lee C, Lee M, Hsieh J . The Role and Mechanism of Epithelial-to-Mesenchymal Transition in Prostate Cancer Progression. Int J Mol Sci. 2017; 18(10). PMC: 5666761. DOI: 10.3390/ijms18102079. View

5.
Bu W, Wang Z, Meng L, Li X, Liu X, Chen Y . Disulfiram inhibits epithelial-mesenchymal transition through TGFβ-ERK-Snail pathway independently of Smad4 to decrease oral squamous cell carcinoma metastasis. Cancer Manag Res. 2019; 11:3887-3898. PMC: 6504671. DOI: 10.2147/CMAR.S199912. View